Parkinson’s disease drug, Xadago, gets FDA nod
by Press Release from Outbreak News Today on (#2GM3Y)
The U.S. Food and Drug Administration today approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson's disease who are currently taking levodopa/carbidopa and experiencing "off" episodes. An "off" episode is a time when a patient's medications are not working well, causing an increase in Parkinson's symptoms, such as tremor and difficulty walking. ["]
The post Parkinson's disease drug, Xadago, gets FDA nod appeared first on Outbreak News Today.